Pharmaceuticals

Beyond the headlines of consolidation, an invisible digital and logistical network is empowering independent medical clinics. Here’s how it works.

A Chinese firm's historic USFDA approval for a complex generic drug ingredient signals a major shift in the global pharma supply chain and promises cheaper medicines.

A new partnership is bringing advanced, U.S.-based manufacturing to a rare cancer drug, aiming to solve daily patient challenges and bolster national supply chains.

With a cash runway into 2029, Avalyn Pharma is advancing a novel inhaled drug platform, hitting key clinical milestones to challenge an oral-dominated market.

Early data for Sutro Biopharma's STRO-004 offers a glimmer of hope for advanced cancer patients. We look at the tech, the trials, and the financial tightrope.

A new partnership aims to bring the first FDA-approved, oral ketamine pill for depression to your home, using AI and real-world data to ensure safety.

COSCIENS Biopharma boasts a dramatic financial turnaround, but its strategic move to exit SEC oversight shifts the risk-reward calculus for investors.

Aardvark Therapeutics faces a pivotal moment as an FDA clinical hold halts its lead drug trial, leaving the Prader-Willi Syndrome community waiting.

Kodiak Sciences launches a pivotal trial for a new drug aiming to best current treatments for diabetic eye disease. Is this the future of vision care?

A novel dual-action antibody shows remarkable durability in Phase 2 trials, offering a potential six-month dosing schedule for millions with chronic sinusitis.

A new report reveals undiagnosed testosterone deficiency could cost the U.S. up to $525 billion, but the real story is about the millions of men being missed.

Quebec's funding for Roche's Itovebi offers new hope for breast cancer patients, but its complex approval reveals a national struggle over drug costs and access.

A new platform offers physicians 24/7 access to 'lifelike' AI pharma reps. We analyze the tech, the immense regulatory risks, and the potential to level the playing field.

With a strong cash position and key clinical trials advancing for ALS and FTD, Coya is executing a disciplined strategy to tackle neurodegenerative diseases.

The consumer health giant is buying back $2B in bonds to refinance its debt. It's a bold play on interest rates and a declaration of its financial independence.

With the appointment of Dr. Jeffrey Sherman, Kalohexis signals a major push to conquer the challenging metabolic disease market with its novel pipeline.

The biotech has gone all-in on its lead drug, bel-sar, cutting 20% of staff and shelving a promising bladder cancer program to secure its financial future.

With a massive Series B and the launch of a Phase 3 study, Vaderis Therapeutics is poised to deliver the first-ever approved therapy for a long-neglected rare disease.

As Johnson & Johnson prepares for a key investor conference, its strategy hinges on a potent mix of new drugs, robotic surgery, and a leaner focus.

With promising early data and a robust balance sheet, Palisade Bio is advancing its targeted IBD therapy, PALI-2108, into crucial Phase 2 trials.